Literature DB >> 33643047

Negative Impact of Sigma-1 Receptor Agonist Treatment on Tissue Integrity and Motor Function Following Spinal Cord Injury.

Alise Lattard1, Gaëtan Poulen1,2, Sylvain Bartolami1, Yannick N Gerber1, Florence E Perrin1,3.   

Abstract

In traumatic spinal cord injury, the initial trauma is followed by a cascade of impairments, including excitotoxicity and calcium overload, which ultimately induces secondary damages. The sigma-1 receptor is widely expressed in the central nervous system and is acknowledged to play a key role in calcium homeostasis. Treatments with agonists of the sigma-1 receptor induce beneficial effects in several animal models of neurological diseases. In traumatic injury the use of an antagonist of the sigma-1 receptor reversed several symptoms of central neuropathic pain. Here, we investigated whether sigma-1 receptor activation with PRE-084 is beneficial or detrimental following SCI in mice. First, we report that PRE-084 treatment after injury does not improve motor function recovery. Second, using ex vivo diffusion weighted magnetic resonance imaging completed by histological analysis, we highlight that σ1R agonist treatment after SCI does not limit lesion size. Finally, PRE-084 treatment following SCI decreases NeuN expression and increases astrocytic reactivity. Our findings suggest that activation of sigma-1 receptor after traumatic spinal cord injury is detrimental on tissue preservation and motor function recovery in mice.
Copyright © 2021 Lattard, Poulen, Bartolami, Gerber and Perrin.

Entities:  

Keywords:  PRE-084; gliosis; motor function; neuromuscular junction; sigma 1 receptor; spinal cord injury

Year:  2021        PMID: 33643047      PMCID: PMC7902910          DOI: 10.3389/fphar.2021.614949

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  15 in total

1.  A "DIRECT-COLORING" THIOCHOLINE METHOD FOR CHOLINESTERASES.

Authors:  M J KARNOVSKY; L ROOTS
Journal:  J Histochem Cytochem       Date:  1964-03       Impact factor: 2.479

Review 2.  PRE-084 as a tool to uncover potential therapeutic applications for selective sigma-1 receptor activation.

Authors:  Zeinab Y Motawe; Salma S Abdelmaboud; Javier Cuevas; Jerome W Breslin
Journal:  Int J Biochem Cell Biol       Date:  2020-07-12       Impact factor: 5.085

Review 3.  Sigma-1 (σ1) Receptor in Memory and Neurodegenerative Diseases.

Authors:  Tangui Maurice; Nino Goguadze
Journal:  Handb Exp Pharmacol       Date:  2017

4.  Gender-related differences in recovery of locomotor function after spinal cord injury in mice.

Authors:  M Farooque; Z Suo; P M Arnold; M J Wulser; C-T Chou; R W Vancura; S Fowler; B W Festoff
Journal:  Spinal Cord       Date:  2006-03       Impact factor: 2.772

5.  Longitudinal Magnetic Resonance Imaging Analysis and Histological Characterization after Spinal Cord Injury in Two Mouse Strains with Different Functional Recovery: Gliosis as a Key Factor.

Authors:  Harun N Noristani; Guillaume P Saint-Martin; Maïda Cardoso; Rahima Sidiboulenouar; Matthias Catteau; Christophe Coillot; Christophe Goze-Bac; Florence E Perrin
Journal:  J Neurotrauma       Date:  2018-08-10       Impact factor: 5.269

6.  Sigma receptors suppress multiple aspects of microglial activation.

Authors:  Aaron A Hall; Yelenis Herrera; Craig T Ajmo; Javier Cuevas; Keith R Pennypacker
Journal:  Glia       Date:  2009-05       Impact factor: 7.452

7.  Selective sigma receptor agonist 2-(4-morpholinethyl)1-phenylcyclohexanecarboxylate (PRE084) promotes neuroprotection and neurite elongation through protein kinase C (PKC) signaling on motoneurons.

Authors:  M-S Guzmán-Lenis; X Navarro; C Casas
Journal:  Neuroscience       Date:  2009-04-05       Impact factor: 3.590

Review 8.  The Role of Sigma-1 Receptor, an Intracellular Chaperone in Neurodegenerative Diseases.

Authors:  Botond Penke; Livia Fulop; Maria Szucs; Ede Frecska
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

9.  Repeated Sigma-1 Receptor Antagonist MR309 Administration Modulates Central Neuropathic Pain Development After Spinal Cord Injury in Mice.

Authors:  Sílvia Castany; Xavier Codony; Daniel Zamanillo; Manuel Merlos; Enrique Verdú; Pere Boadas-Vaello
Journal:  Front Pharmacol       Date:  2019-03-22       Impact factor: 5.810

10.  A Combination of Ex vivo Diffusion MRI and Multiphoton to Study Microglia/Monocytes Alterations after Spinal Cord Injury.

Authors:  Harun N Noristani; Hassan Boukhaddaoui; Guillaume Saint-Martin; Pauline Auzer; Rahima Sidiboulenouar; Nicolas Lonjon; Eric Alibert; Nicolas Tricaud; Christophe Goze-Bac; Christophe Coillot; Florence E Perrin
Journal:  Front Aging Neurosci       Date:  2017-07-19       Impact factor: 5.750

View more
  4 in total

Review 1.  Emerging Benefits: Pathophysiological Functions and Target Drugs of the Sigma-1 Receptor in Neurodegenerative Diseases.

Authors:  Ning-Hua Wu; Yu Ye; Bin-Bin Wan; Yuan-Dong Yu; Chao Liu; Qing-Jie Chen
Journal:  Mol Neurobiol       Date:  2021-08-12       Impact factor: 5.590

2.  Reduced GFAP Expression in Bergmann Glial Cells in the Cerebellum of Sigma-1 Receptor Knockout Mice Determines the Neurobehavioral Outcomes after Traumatic Brain Injury.

Authors:  Gundega Stelfa; Edijs Vavers; Baiba Svalbe; Rinalds Serzants; Anna Miteniece; Lasma Lauberte; Solveiga Grinberga; Baiba Gukalova; Maija Dambrova; Liga Zvejniece
Journal:  Int J Mol Sci       Date:  2021-10-27       Impact factor: 5.923

3.  Therapeutic Effect of Exosomes Derived From Stem Cells in Spinal Cord Injury: A Systematic Review Based on Animal Studies.

Authors:  Cangyu Zhang; Rongrong Deng; Guangzhi Zhang; Xuegang He; Haiwei Chen; Bao Chen; Lin Wan; Xuewen Kang
Journal:  Front Neurol       Date:  2022-03-10       Impact factor: 4.003

4.  Exosomes Derived from Nerve Stem Cells Loaded with FTY720 Promote the Recovery after Spinal Cord Injury in Rats by PTEN/AKT Signal Pathway.

Authors:  Jianbin Chen; Can Zhang; Shouye Li; Zheming Li; Xiaojing Lai; Qingqing Xia
Journal:  J Immunol Res       Date:  2021-07-14       Impact factor: 4.818

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.